Reanna K. Panagides

Reanna K. Panagides


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2022 in Journal of Cancer Education
Verified
Journal Article
Open access
PDF file
RPReanna K. Panagides
Reanna K. Panagides
NVNoelle Voges
Noelle Voges
JOJanaye Oliver
Janaye Oliver
DBDebbie Bridwell
Debbie Bridwell
EMEmma Mitchell
Emma Mitchell
HPV vaccination series completion rates have increased steadily in the USA, yet specific areas continue to be burdened by HPV-related cancers, including rural areas of Virginia. The primary purpose of this study is to compare the impact of an community driven educational film about HPV on intention to vaccinate and knowledge gained in urban and rural areas of Virginia. From October 2016 to September 2019, the CDC-approved documentary “Someone You Love: The HPV Epidemic” was screened and followed by a Q&A session. Intention to vaccinate and knowledge gained after seeing the DVD intervention were measured through a pre-post-survey and analyzed data using chi-squared tests. The sample included males and females of all races and ages 18+ that identified as either student, parent/guardian, and/or healthcare provider from rural and urban geographical areas. Changes in knowledge about HPV were statistically significant in two out of seven questions (p < 0.05). Changes in attitude were statistically significant in every attitude-based question about HPV (p < 0.05). There were significant differences in knowledge gained and attitudes towards the HPV vaccine when comparing urban and rural locations as well. More research is needed to explore the efficacy of community-based interventions to increase uptake and series completion of HPV vaccination, particularly in rural areas most impacted by HPV-associated cancers.

6 July 2025 in International Journal of Nursing Studies Advances
Verified
Journal Article
Open access
RPReanna K. Panagides
Reanna K. Panagides
JKJessica Keim-Malpass
Jessica Keim-Malpass
Clinical algorithms are commonly used as decision-support tools, incorporating patient-specific characteristics to predict health outcomes. Risk calculators are clinical algorithms particularly suited for resource allocation based on risk estimation. Although these calculators typically use physiologic data in estimation, they frequently include demographic variables such as race, sex, and age as well. In recent years, the inclusion of race as an input variable has been scrutinized for being reductive, serving as a poor proxy for biological differences, and contributing to the inequitable distribution of services. Little attention has been given to other demographic features, such as sex and age, and their potential to produce similar consequences. By applying a framework for understanding sources of harm throughout the machine learning life cycle and presenting case studies, this paper aims to examine sources of potential harms (i.e. representational and allocative harm) associated with including sex and age in clinical decision-making algorithms, particularly risk calculators. In doing so, this paper demonstrates how systematic discrimination, reductive measurement practices, and observed differences in risk estimation between demographic groups contribute to representational and allocative harm caused by including sex and age in clinical algorithms used for resource distribution. This paper ultimately, urges clinicians to scrutinize the practice of including reductive demographic features (i.e. race, binary-coded sex, and chronological age) as proxies for underlying biological mechanisms in their risk estimations as it violates the bioethical principles of justice and nonmaleficence. Practicing clinicians, including nurses, must have an underlying model literacy to address potential biases introduced in algorithm development, validation, and clinical practice.

10 September 2024 in AI
Verified
Journal Article
Open access
PDF file
RPReanna K. Panagides
Reanna K. Panagides
SFSean H. Fu
Sean H. Fu
SJSkye H. Jung
Skye H. Jung
ASAbhishek Singh
Abhishek Singh
RMRose Eluvathingal Muttikkal
Rose Eluvathingal Muttikkal
RHRick Hamilton
Rick Hamilton
Over the past decade, focused ultrasound (FUS) has emerged as a promising therapeutic modality for various medical conditions. However, the exponential growth in the published literature on FUS therapies has made the literature review process increasingly time-consuming, inefficient, and error-prone. Machine learning approaches offer a promising solution to address these challenges. Therefore, the purpose of our study is to (1) explore and compare machine learning techniques for the text classification of scientific abstracts, and (2) integrate these machine learning techniques into the conventional literature review process. A classified dataset of 3588 scientific abstracts related and unrelated to FUS therapies sourced from the PubMed database was used to train various traditional machine learning and deep learning models. The fine-tuned Bio-ClinicalBERT (Bidirectional Encoder Representations from Transformers) model, which we named FusBERT, had comparatively optimal performance metrics with an accuracy of 0.91, a precision of 0.85, a recall of 0.99, and an F1 of 0.91. FusBERT was then successfully integrated into the literature review process. Ultimately, the integration of this model into the literature review pipeline will reduce the number of irrelevant manuscripts that the clinical team must screen, facilitating efficient access to emerging findings in the field.

7 January 2025 in Journal of Forensic and Legal Medicine
Verified
Journal Article
Closed access
RPReanna K. Panagides
Reanna K. Panagides
KKKaren Kafadar
Karen Kafadar
KLKathryn Laughon
Kathryn Laughon

16 April 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
KMKathleen A McManus
Kathleen A McManus
ERErin Q Rogers
Erin Q Rogers
ASAmber Steen
Amber Steen
AKAmy Killelea
Amy Killelea
THTim Horn
Tim Horn
JKJessica Keim-Malpass
Jessica Keim-Malpass
Background: AIDS Drug Assistance Programs (ADAPs), a key part of the federally funded Ryan White HIV/AIDS Program, provide antiretroviral therapy (ART) to low-income and uninsured or underinsured people with HIV. As long as they meet federal regulations, jurisdictions maintain flexibility in implementing ADAPs, allowing for a range of operational and programmatic options, including eligibility criteria, formulary design for ART (and non-ART) drugs, and the nature and character of insurance support. These programmatic and policy decisions ultimately impact ADAP client outcomes, including engagement in care, differences in the populations benefiting from ADAP, and viral suppression rates. Despite ADAPs achieving an 85% national average viral suppression rate, this falls short of the 90% goal needed to end the HIV epidemic, and no formal evaluation has examined how specific operational or policy factors drive success across states. Objective: This qualitative study aims to examine how operational, organizational, and contextual factors shape the ability of ADAPs to improve viral suppression rates among people with HIV enrolled in ADAPs, specifically by identifying the mechanisms that facilitate high performance and viral suppression for all people with HIV. Results will inform how viral suppression outcomes could be improved through policy, program, operational, and organizational changes in ADAP design and implementation. Methods: Using a qualitative descriptive approach guided by the Consolidated Framework for Implementation Research, we conducted semistructured interviews with state-level ADAP leaders, operational and programmatic decision-makers, and staff. Interview questions covered 5 domains: leadership and staffing; operations, integration, and collaboration; formulary design and treatment; eligibility and enrollment; and innovation and implementation. Qualitative data from the interviews will be analyzed using deductive and inductive approaches along with situational mapping. Results: This study was funded in April 2023. In total, 33 individuals from 16 states have participated in this qualitative study, resulting in a participation rate of 31.4% (16/51). States from all 4 US census regions were represented. Interviews were conducted between February 12, 2025, and March 20, 2025. As of March 2026, data analysis is underway. Conclusions: We anticipate that the study will highlight features, organizational practices, and operational norms that contribute to the successes of ADAPs with high rates of viral suppression. Successful completion of this analysis will provide evidence to inform state and federal regulations, program development, resource allocation, and prioritization to advance the goal of helping people achieve viral suppression and interrupt HIV transmission, which is a vital public health objective. Using other data alongside our qualitative findings, we can provide context for the environment in which these programs or policies impact ADAP clients and the broader public health objectives of the Ryan White HIV/AIDS Program. Ultimately, we expect that disseminating these results will support improvements in viral suppression, enhancing both individual health outcomes and public health. International Registered Report Identifier (IRRID): DERR1-10.2196/90008

16 July 2026 in JMIR Preprints
Verified
Preprint
Open access
AKAmy Killelea
Amy Killelea
ERErin Q Rogers
Erin Q Rogers
ASAmber Steen
Amber Steen
THTim Horn
Tim Horn
RPReanna K. Panagides
Reanna K. Panagides
KMKathleen A. McManus
Kathleen A. McManus
BACKGROUND AIDS Drug Assistance Programs (ADAPs) are a critical safety net within the federal Ryan White HIV/AIDS Program. ADAPs are operated by state and territorial health departments and provide HIV medication access and insurance assistance for low-income people with HIV (PWH). However, the most recent qualitative study assessment of ADAPs was over 14 years ago. OBJECTIVE The purpose of this study was to better understand administrative, programmatic, clinical, and financial considerations that enable ADAPs to support adherence to HIV medications and ultimately achieve viral suppression, treating uninterrupted structural access to medications as a proximate determinant of downstream adherence behavior. METHODS We conducted a secondary qualitative analysis of interviews with state health department HIV program leaders and ADAP staff; participation was at the state level, with 16 states and 33 individual participants enrolled using maximum variance sampling. Coding was guided by the Exploration, Preparation, Implementation, and Sustainment (EPIS). RESULTS Our secondary analysis identified three domains of ADAP programmatic and policy decisions that support medication adherence: eligibility policies (income thresholds, recertification requirements, and re-enrollment flexibilities), formulary design (open vs. limited formularies, inclusion of newer long-acting therapies, and non-ART medications), and pharmacy access policies (network breadth, dispensing location, and multi-month dispensing). Across each domain, programs described facilitators that reduced medication interruptions and barriers that created gaps in ART access for low-income PWH. CONCLUSIONS ADAPs play a central role in supporting medication adherence for low-income PWH through concrete programmatic and policy decisions. Flexible eligibility policies, broad formularies, and accessible pharmacy networks each reduce barriers to uninterrupted ART access. These findings are particularly timely: as of early 2026, at least two ADAPs have established waiting lists, and multiple states have reduced financial eligibility thresholds or formulary coverage in response to budget pressures. The policies described in this study as facilitators of adherence are the same policies being curtailed. Given this study’s findings, removal of these programs features would be expected to reduce the medication adherence and viral suppression gains ADAPs have achieved for the low-income PWH they serve.